In the latest post on the the IVI-sponsored Health Affairs blog series, Neeraj Sood, Tiffany Shih, Karen Van Nuys and Dana Goldman present the findings of their study examining the flow of funds in the pharmaceutical distribution system, suggesting that greater transparency and granularity would be beneficial in the reporting of financials from all sectors. [...]

In a post on the the IVI-sponsored Health Affairs blog series, Henry Grabowski and Richard Manning offer a rebuttal to a recent Health Affairs blog commentary by Nancy Yu, Zachary Helms, and Peter Bach on the subject of drug pricing. In their rebuttal, Grabowski and Manning caution that the premise of the earlier blog post [...]

In a recent post on the IVI-sponsored Health Affairs blog series, Michael Carrier and Steve Shadowen examine the practice of "product hopping," in which drug manufacturers can delay a generic introduction through product reformulation. In addition to presenting some of the prevailing issues before the courts, the authors also propose a new framework to keep the [...]

In a post on the IVI-sponsored Health Affairs blog series,Josh Seidman, Margaret Anderson, Domitilla Masi, Melea Atkins and Maureen Japha examine the role of patient perspectives in assessing value in healthcare, focusing on the Avalere-FasterCures Patient-Perspective Value Framework as an example of progress toward a more patient-centered approach to value assessment. Read the full article [...]